H.R.5402 - Protecting America's Life Saving Medicines Act of 2019116th Congress (2019-2020) |
|Sponsor:||Rep. Gottheimer, Josh [D-NJ-5] (Introduced 12/11/2019)|
|Committees:||House - Ways and Means; Energy and Commerce|
|Latest Action:||House - 12/11/2019 Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
- Passed House
- Passed Senate
- To President
- Became Law
Summary: H.R.5402 — 116th Congress (2019-2020)All Information (Except Text)
Introduced in House (12/11/2019)
Protecting America's Life Saving Medicines Act of 2019
This bill directs the Food and Drug Administration (FDA) to conduct a study on drugs that are currently being tested and are unlikely to be approved, but would, if approved, address an unmet medical need for the treatment of a serious or life threatening disease or condition or a rare disease or condition (high-risk, high-reward drugs). The FDA must submit to the Department of the Treasury a list of such high-risk, high-reward drugs not later than 180 days after the completion of the study.
The bill also allows a new tax credit for 25% of the clinical testing expenses for high-risk, high-reward drugs.